Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

Andrea B. Apolo, MD
Published: Wednesday, Jun 28, 2017



Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

In the combination of cabozantinib plus nivolumab (Opdivo) and cabozantinib plus ipilimumab (Yervoy), the typical side effects of each agent were shown. There was no synergy between the toxicities though, which is an encouraging sign, says Apolo.

The recommended phase II dose is cabozantinib at 40 mg (CHECK), nivolumab at 3 mg/kg, and ipilimumab at 1 mg/kg.
 


Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

In the combination of cabozantinib plus nivolumab (Opdivo) and cabozantinib plus ipilimumab (Yervoy), the typical side effects of each agent were shown. There was no synergy between the toxicities though, which is an encouraging sign, says Apolo.

The recommended phase II dose is cabozantinib at 40 mg (CHECK), nivolumab at 3 mg/kg, and ipilimumab at 1 mg/kg.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x